1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY USED FOR THE STUDY 21
1.5 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Secondary sources 24
2.1.2 PRIMARY DATA 25
2.2 MARKET ESTIMATION METHODOLOGY 26
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 27
2.2.2 PROCEDURE-BASED MARKET ESTIMATION 27
2.2.3 PRIMARY RESEARCH VALIDATION 28
2.3 DATA TRIANGULATION 29
2.4 RESEARCH ASSUMPTIONS 30
2.5 RESEARCH LIMITATIONS 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 36
4.1 SEPSIS DIAGNOSTICS: MARKET OVERVIEW 36
4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 37
4.3 GEOGRAPHIC ANALYSIS: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND REGION 38
4.4 APAC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY AND END USER 38
4.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN 39
4.6 GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DINAMICS 40
5.2.1 DRIVERS 41
5.2.1.1 High incidence of sepsis 41
5.2.1.2 Rising incidence of hospital-acquired infections 42
5.2.1.3 Growing funding for sepsis-related research 42
5.2.2 RESTRAINTS 43
5.2.2.1 Unfavorable reimbursement scenario 43
5.2.2.2 High cost of automated diagnostic devices 43
5.2.3 OPPORTUNITIES 43
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis 43
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis 44
5.2.4 CHALLENGES 44
5.2.4.1 Lack of standard protocols and awareness 44
5.2.4.2 Shortage of skilled healthcare professionals 45

6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 46
6.1 INTRODUCTION 47
6.2 BLOOD CULTURE 47
6.2.1 BLOOD CULTURE HOLDS THE LARGEST SHARE OF THE TECHNOLOGY MARKET 47
6.3 IMMUNOASSAYS 50
6.3.1 PRODUCT DEVELOPMENT EFFORTS BY MAJOR PLAYERS HAVE ENSURED DEMAND FOR IMMUNOASSAYS 50
6.4 MOLECULAR DIAGNOSTICS 53
6.4.1 POLYMERASE CHAIN REACTION 55
6.4.1.1 PCR holds the largest share of the molecular diagnostics market 55
6.4.2 MICROARRAYS 57
6.4.2.1 Simultaneous analysis capabilities, accuracy, and rapidity have driven the use of microarrays 57
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION 60
6.4.3.1 PNA-FISH kits allow for the rapid diagnosis of BSIs 60
6.4.4 SYNDROMIC PANEL-BASED TESTING 61
6.4.4.1 High costs and accuracy issues have affected test adoption 61
6.5 FLOW CYTOMETRY 64
6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY RESTRAINT IN THIS MARKET SEGMENT 64
6.6 MICROFLUIDICS 66
6.6.1 GROWING ADOPTION OF ADVANCED & RAPID TESTING WILL FAVOR MARKET GROWTH IN THIS SEGMENT 66
6.7 BIOMARKERS 68
6.7.1 DESPITE POTENTIAL, NO SINGLE IDEAL BIOMARKER HAS BEEN IDENTIFIED FOR SEPSIS DIAGNOSTICS 68

7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 71
7.1 INTRODUCTION 72
7.2 BLOOD CULTURE MEDIA 72
7.2.1 BLOOD CULTURE MEDIA DOMINATE THE PRODUCTS MARKET 72
7.3 ASSAYS & REAGENTS 73
7.3.1 INCREASING AWARENESS HAS DRIVEN THE USE OF ASSAYS & REAGENTS 73
7.4 INSTRUMENTS 74
7.4.1 MARKET IS CHARACTERIZED BY A SHIFT FROM TRADITIONAL & MANUAL INSTRUMENTS TO AUTOMATED SYSTEMS 74
7.5 SOFTWARE 75
7.5.1 RISING USE OF AUTOMATED INSTRUMENTS WILL ENSURE DEMAND FOR SOFTWARE 75

8 SEPSIS DIAGNOSTICS MARKET, BY METHOD 76
8.1 INTRODUCTION 77
8.2 CONVENTIONAL DIAGNOSTICS 77
8.2.1 CONVENTIONAL DIAGNOSTICS HOLDS LARGEST MARKET SHARE 77
8.3 AUTOMATED DIAGNOSTICS 78
8.3.1 AUTOMATED DIAGNOSTICS SEGMENT TO GROW AT THE HIGHEST CAGR 78

9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN 80
9.1 INTRODUCTION 81
9.2 BACTERIAL SEPSIS 81
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 82
9.2.1.1 Gram-negative bacteria cause ~50% of sepsis infections 82
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 83
9.2.2.1 Cases of sepsis caused by gram-positive bacteria have risen in recent years 83
9.3 FUNGAL SEPSIS 84
9.3.1 FUNGEMIA IS THE SECOND-BIGGEST CAUSE OF BLOODSTREAM INFECTIONS 84
9.4 OTHER PATHOGENS 85

10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE 86
10.1 INTRODUCTION 87
10.2 LABORATORY TESTS 87
10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND PREFERRED MODE OF TESTING 87
10.3 POINT-OF-CARE TESTS 88
10.3.1 RAPIDITY AND CONVENIENCE HAVE DRIVEN DEMAND FOR POC TESTS 88

11 SEPSIS DIAGNOSTICS MARKET, BY END USER 90
11.1 INTRODUCTION 91
11.2 HOSPITALS 91
11.2.1 HOSPITALS HOLD THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET 91
11.3 PATHOLOGY & REFERENCE LABORATORIES 92
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABILITY AS WELL AS THE BENEFITS OF BUNDLED SERVICES 92
?
11.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 93
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS HAVE ENSURED DEMAND FOR MARKET PRODUCTS IN THIS SEGMENT 93

12 SEPSIS DIAGNOSTICS MARKET, BY REGION 94
12.1 INTRODUCTION 95
12.2 NORTH AMERICA 95
12.2.1 US 99
12.2.1.1 US is the largest market for sepsis diagnostics 99
12.2.2 CANADA 101
12.2.2.1 Growing availability of sepsis diagnostic products to support market growth in Canada 101
12.3 EUROPE 103
12.3.1 GERMANY 106
12.3.1.1 Germany accounted for the largest share of the European market 106
12.3.2 FRANCE 107
12.3.2.1 High incidence and rising awareness have supported the demand for sepsis diagnostics in France 107
12.3.3 UK 109
12.3.3.1 Government support and rising awareness are key drivers in the UK 109
12.3.4 ITALY 110
12.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain the market growth 110
12.3.5 SPAIN 111
12.3.5.1 Rising sepsis incidence to drive market growth in Spain 111
12.3.6 REST OF EUROPE 112
12.4 ASIA PACIFIC 113
12.4.1 JAPAN 117
12.4.1.1 Significant growth in pneumonia and infectious disease incidence to support market growth in Japan 117
12.4.2 CHINA 118
12.4.2.1 Healthcare infrastructure improvements to support market growth in China 118
12.4.3 INDIA 120
12.4.3.1 Increasing patient population and rising number of surgical procedures are key growth drivers in India 120
12.4.4 AUSTRALIA 122
12.4.4.1 Increasing number of sepsis treatment procedures indicates growth potential in the Australian market 122
12.4.5 SOUTH KOREA 123
12.4.5.1 Rising healthcare spending supports market growth in South Korea 123
12.4.6 REST OF ASIA PACIFIC 124
?
12.5 LATIN AMERICA 125
12.5.1 BRAZIL 129
12.5.1.1 Brazil accounted for the largest share of the LATAM market 129
12.5.2 MEXICO 130
12.5.2.1 Rising medical tourism to support market growth in Mexico 130
12.5.3 REST OF LATIN AMERICA 131
12.6 MIDDLE EAST & AFRICA 132
12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS IS DRIVING SEPSIS OCCURRENCE 132
13 COMPETITIVE LANDSCAPE 135
13.1 OVERVIEW 135
13.2 MARKET SHARE ANALYSIS 136
13.3 COMPETITIVE SCENARIO 137
13.3.1 PRODUCT LAUNCHES AND APPROVALS, 2016–2020 137
13.3.2 PARTNERSHIPS AND COLLABORATIONS, 2016–2020 137
13.3.3 MERGERS AND ACQUISITIONS, 2016–2020 138
13.3.4 MARKET EXPANSION, 2016–2020 138
13.4 COMPETITIVE LEADERSHIP MAPPING 138
13.4.1 VISIONARY LEADERS 139
13.4.2 INNOVATORS 139
13.4.3 DYNAMIC DIFFERENTIATORS 139
13.4.4 EMERGING COMPANIES 139
14 COMPANY PROFILES 141
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 BIOM?RIEUX 141
14.2 BECTON, DICKINSON AND COMPANY 144
14.3 DANAHER 146
14.4 T2 BIOSYSTEMS 150
14.5 LUMINEX 152
14.6 ROCHE DIAGNOSTICS 154
14.7 THERMO FISHER SCIENTIFIC 157
14.8 BRUKER CORPORATION 160
14.9 ABBOTT 163
14.10 IMMUNEXPRESS 165
14.11 RESPONSE BIOMEDICAL 166
14.12 AXIS-SHIELD DIAGNOSTICS 167
14.13 CYTOSORBENTS 168
14.14 MITSUBISHI CHEMICAL EUROPE 171
?
14.15 EKF DIAGNOSTICS 172
14.16 EMERGING PLAYERS 174
14.16.1 SEEGENE 174
14.16.2 GENMARK DIAGNOSTICS 174
14.16.3 BODITECH MED 175
14.16.4 ALPHA LABORATORIES 176
14.16.5 ALIFAX S.R.L. 177
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
15 APPENDIX 178
15.1 DISCUSSION GUIDE 178
15.2 KNOWLEDGE STORE 195
15.3 AVAILABLE CUSTOMIZATIONS 197
15.4 RELATED REPORTS 198
15.5 AUTHOR DETAILS 199